维也那会议释放更多支架消息

September 4, 2007, 10:33 am
Stents Waltz Through Vienna Meeting
Posted by Jacob Goldstein
2007年9月4日
支架风波在维也纳会议上继续上演
作者：雅各布－戈登斯坦

There’s a bunch of new information on the risks (or lack of them) from drug-coated stents being presented at the European Society of Cardiology’s big annual meeting in Vienna. But how to piece together the findings into a cohesive picture is tricky and inconclusive, suggesting that the latest data won’t resolve the ongoing debate over the safety and proper use of the devices.
在维也纳举行的欧洲心脏病学会大型年会上，公布了更多关于药物涂层支架（DES）风险的新消息。但是如何把这些新发现整合起来仍很微妙和不确定，表明这些最新的数据对于解决目前关于DES的安全性和合理使用不会有彻底帮助。

On the bright side for stent makers, including Johnson & Johnson and Boston Scientific, an absence of more bad news on stents may be enough to constitute good news. Overall, this year’s meeting is better than last year’s for stent makers “if for no other reason than there have been no major negative surprises,” Lehman Brothers’ analyst Tony Butler writes in a note this morning.
但是，对于支架制造商强生和波士顿科技公司来说，没有更多关于支架的坏消息就已经可以称得上“好消息”了。来自莱曼兄弟公司的分析师托尼－巴特在今天早上的备忘中写到，“总的来说，今年的ESC年会对于支架制造商来说，情况要比去年好一些。如果没有出现比之前已有的证据，那么就不会再有负面影响了。”

Still, the picture isn’t particularly rosy, with continued uncertainty over the devices’ safety, and a stent market unlikely to see short-term growth, he writes. Butler estimates that stent sales will account for less than 10% of profit for Abbott Laboratories, which is likely to introduce its first U.S. stent soon.
他写到，由于在支架安全性讨论仍存在不确定性，关于DES的最后定论并不是很有希望，而支架市场也不大可能在短期内出现增长。据他的估计，由于雅培公司很有可能将于不久获得在美国支架销售权，支架销售利润将会削减10%。

One analysis presented at the meeting found that heart-attack patients who received drug-coated stents were at a higher risk of death in the two years following their heart attack than patients who received bare-metal stents. That study, described here, was based on an analysis of patients from 94 hospitals in 14 countries.
本次年会上公布的一份分析指出，相比于裸金属支架，接受药物涂层支架的心脏病患者在术后两年内具有更高的死亡风险。该研究是基于14个国家94家医院的综合分析得出。

But another analysis (abstract here) of about 35,000 patients in Sweden found that those who received drug-coated stents had the same risk of heart attack and death as those who received bare-metal stents. An earlier analysis of the same registry by the same author, Stefan James, had revealed an increased risk in fatal blood clots among patients who received drug-eluting stents. The shift may be a result of more cautious use of the devices, or more careful management of patients who receive them, according to the Associated Press.
但是在另一份研究中，接受药物涂层支架的患者和接受裸金属支架的患者具有相同的心脏病风险。该研究来自于瑞典的35,000名患者。而该研究作者Stefan James在同一地方进行的一份早期研究则表明，在接受药物涂层支架的患者中具有更高的血栓风险。根据美联社的报道，两分研究的差异可能在于对于支架的谨慎使用，或者是对接受DES的患者进行更细致的看护。

But James suggested that, despite his newest findings, it would be premature to conclude that drug-coated stents don’t carry a higher risk of blood clots. “The risk is not eliminated,” he said, according to AP. “We haven’t solved the clot problem yet.”
尽管取得了新的发现，但是James认为要得出“药物涂层支架没有更高血栓风险的结论”还为时过早。他对美联社的记者说，“血栓的风险依然存在，我们并没有很好的解决。”